Polyrizon Completes All Five Clinical Sites for NASARIX™ Trial, Moves Toward 120-Patient Enrollment

summarizeSummary

Polyrizon completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker trial and disclosed full study design, advancing toward enrollment of 120 patients timed to allergy seasons.

check_boxKey Events · Product Development and Regulatory · PLRZ

• All Five Clinical Sites Contracted

  Polyrizon completed agreements with the fourth and fifth U.S. clinical sites, finalizing the full network for the NASARIX™ Allergy Blocker study.

• Trial Design Disclosed

  The first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm trial enrolling up to 120 patients in a 1:1 ratio to NASARIX™ or isotonic saline control.

• Primary Endpoint Set

  Efficacy will be measured by mean daily reflective Total Nasal Symptom Score (rTNSS) over the first 14 treatment days, with safety assessed via adverse events and tolerability.

• Enrollment Timing Tied to Allergy Seasons

  Patient pre-screening and enrollment will coincide with seasonal allergen exposure, with local pollen counts and weather monitored to support recruitment timing.

auto_awesomeAnalysis · PLRZ · Industrial Applications And Services

Polyrizon has now contracted all five U.S. clinical sites for its NASARIX™ Allergy Blocker first-in-human study, a key operational milestone that shifts the program from preparation to execution. The filing details the trial design: 120 patients randomized 1:1 to NASARIX™ or saline control, with a primary endpoint of rTNSS over 14 days. Enrollment is timed to allergy seasons, meaning patient recruitment will ramp as pollen counts rise. This is a meaningful step for a development-stage biotech with a $22.8M market cap, as it de-risks the clinical timeline and brings the company closer to generating efficacy data that could support U.S. market entry.